“Anemia” and “rhuepo (recombinant human erythropoietin)” were early fields in uremic cardiomyopathy (Cluster ID #1 and ID #4, Figure 5A), which are attributed to the discovery of anemia-induced cardiac injury in CKD (25) and erythropoietin can mitigate LVH in patients with CKD (9). Here, EPO is linked to chronic kidney disease.